VERVE THERAPEUTICS INC. - COMMON STOCK

5,4700

23-апреля-25 16:45:00

15 мин. задержка

Акции

+0,2200

+4,19%

Сегодняшний диапазон

5,4500 - 5,9576

ISIN

N/A

Источник

NASDAQ

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

31 май 2024 16:01:00 Источник Nasdaq GlobeNewswire
Verve Therapeutics Announces Leadership Update

31 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Verve Therapeutics to Participate in Upcoming Investor Conferences

30 май 2024 16:01:00 Источник Nasdaq GlobeNewswire
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results

08 май 2024 07:00:01 Источник Nasdaq GlobeNewswire
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102

07 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 май 2024 16:01:00 Источник Nasdaq GlobeNewswire
Verve Therapeutics Announces Updates on its PCSK9 Program

02 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

28 мар 2024 16:51:34 Источник Nasdaq GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 мар 2024 16:01:00 Источник Nasdaq GlobeNewswire
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

27 фев 2024 07:30:00 Источник Nasdaq GlobeNewswire
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

01 фев 2024 06:30:00 Источник Nasdaq GlobeNewswire
Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 янв 2024 06:30:11 Источник Nasdaq GlobeNewswire
Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement

01 дек 2023 16:00:00 Источник Nasdaq GlobeNewswire
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement

28 ноя 2023 22:37:08 Источник Nasdaq GlobeNewswire
Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

28 ноя 2023 16:01:51 Источник Nasdaq GlobeNewswire
Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

07 ноя 2023 06:30:00 Источник Nasdaq GlobeNewswire
Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3

31 окт 2023 06:01:28 Источник Nasdaq GlobeNewswire
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia

23 окт 2023 06:30:00 Источник Nasdaq GlobeNewswire
Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023

26 сен 2023 06:30:00 Источник Nasdaq GlobeNewswire
Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

21 сен 2023 16:05:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.